TORONTO, March 12, 2019 (GLOBE NEWSWIRE)
MediPharm Labs Corp. (TSXV: LABS) (OTCQB: MLCPF) (FSE:MLZ) (“MediPharm Labs”), a leader in specialized, research-driven cannabis extraction, distillation, purification and cannabinoid isolation, today announces that it will present at the 31st Annual ROTH Conference in Orange County, California.
MediPharm Labs executive management is scheduled to present at the conference on Tuesday, March 19, at approximately 8:00 a.m. PDT at The Ritz-Carlton hotel in Dana Point. The annual ROTH Conference, hosted by ROTH Capital Partners March 17-19, gathers more than 500 companies and approximately 1,000 investors, featuring presentations from public and private companies in a variety of sectors including healthcare.
About MediPharm Labs Corp.
Founded in 2015, MediPharm Labs has the distinction of being the first company in Canada to become a licensed producer for cannabis oil production under the ACMPR without first receiving a cannabis cultivation licence. This expert focus on cannabis concentrates from our cGMP (current Good Manufacturing Practices) and ISO standard clean rooms and critical environments laboratory, allows MediPharm Labs to produce purified, pharmaceutical-grade cannabis oil and concentrates for advanced derivative products.
MediPharm Labs has invested in an expert, research-driven team, state-of-the-art technology, downstream extraction methodologies and purpose-built facilities to deliver pure, safe and precisely-dosed cannabis products to patients and consumers. MediPharm Labs’ private label program is a high margin business for the Company, whereby it opportunistically procures dry cannabis flower and trim from its numerous product supply partners, to produce proprietary cannabis oil concentrate products for resale globally on a private label basis.
MediPharm Labs was recently named START-UP OF THE YEAR at the Canadian Cannabis Awards.
Through its subsidiary, MediPharm Labs Australia Pty. Ltd., MediPharm has also completed its application process with the federal Office of Drug Control to extract and import medical cannabis products in Australia.
For further information, please contact:
Laura Lepore, Vice President, Investor Relations & Communications
Telephone: 705-719-7425 ext 216
NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSXV) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.